Early studies report extremely poor outcome in AIDS-related Burkitt’s lymphoma treated with standard dose chemotherapy. This poor prognosis is not improved by Highly Active Antiretroviral Therapy (HAART). 53 patients with HIV infection and stage IV Burkitt lymphoma/leukemia (BL) participated a unicentric and prospective clinical trial to evaluate the safety and efficacy of the intensive LMB-86 chemotherapy regimen. The median CD4 cell count was 236 x 106/l. 32 tumors were of the Burkitt type and 21 were Burkitt-like. All patients had stage IV disease with bone marrow involvement in 40 and central nervous system disease in 37. The LMB-86 regimen combined: (1) cytoreductive phase, with low dose cyclophosphamide, vincristine and steroids; (2) induction phase, with 2 consecutive courses of COPADM with high dose (8 g/m2) methotrexate (MTX); (3) consolidation phase with two courses of CYVE with high dose cytarabine and etoposide; (4) maintenance phase, with four courses combining previous drugs with lower dosage.

Thirty eight patients (71.7 %) achieved complete remission after the induction phase. With a median follow-up of 74.1 months (range, 8–153.1), 11 have progressed on therapy or relapsed. The median survival was 14.2 months and 32 patients have died. Most of deaths were due to BL (n=17, 53.1%), 5 (15.6%) to treatment toxicity, 7 (21.9%) to AIDS and 3 (9.4%) to other causes. The 1-year and 2-year estimate survival were 51% (95% CI, 44.1%–57.9%) and 47% (95% CI, 40.1%–53.9%), respectively (figure). Median disease free survival (DFS) was 41.7 months (range, 11.5-not reached) with a 2-year estimate DFS of 59.3%. Using the univariate analysis, four baseline covariates were associated with shorter survival: CD4<200 x 106/L (HR 3.3; 95% IC, 1.6–6.6), CD8 <1500 x 106/L (HR 2.5; 95% IC, 1.1–10), "B" symptoms (HR 3.6; 95% IC, 1.1–11.9), and ECOG score > 2 (HR 2.9, 95% IC, 1.3–6.4). No other HIV covariates, lymphoma baseline data or demographic data were associated with outcome. Using multivariate analysis only association with low CD4 count was significant (p=0.03).

Intensive chemotherapy regimen (LMB-86) containing high dose MTX and cytarabine is highly efficient in stage IV AIDS-related Burkitt’s lymphoma. Toxicity is high but acceptable with regard to the best overall survival reported to date.

Figure
View largeDownload slide

Figure

Topics:
acquired immunodeficiency syndrome, burkitt's lymphoma, chemotherapy regimen, leukemia, antiretroviral therapy, highly active, cytarabine, toxic effect, bone marrow involvement, central nervous system dysfunction, complete remission

Author notes

Corresponding author

2005, The American Society of Hematology
2005
Sign in via your Institution